Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$181.4 million.

  • ImmunityBio's Cash from Investing Activities fell 37887.96% to -$181.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.5 million, marking a year-over-year decrease of 82552.06%. This contributed to the annual value of -$12.2 million for FY2024, which is 5980.96% up from last year.
  • As of Q3 2025, ImmunityBio's Cash from Investing Activities stood at -$181.4 million, which was down 37887.96% from -$16.1 million recorded in Q2 2025.
  • ImmunityBio's 5-year Cash from Investing Activities high stood at $116.7 million for Q2 2022, and its period low was -$181.4 million during Q3 2025.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$8.5 million (2023), whereas its average is -$15.5 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 192640.16% in 2021, then surged by 101232.72% in 2022.
  • ImmunityBio's Cash from Investing Activities (Quarter) stood at -$137.8 million in 2021, then skyrocketed by 86.29% to -$18.9 million in 2022, then skyrocketed by 111.9% to $2.2 million in 2023, then skyrocketed by 337.26% to $9.8 million in 2024, then tumbled by 1944.22% to -$181.4 million in 2025.
  • Its last three reported values are -$181.4 million in Q3 2025, -$16.1 million for Q2 2025, and $4.1 million during Q1 2025.